Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARCIK CD123/33 in R/R AML and BPDCN
NCT07877610Phase 2Recruiting
- Sponsor
- Fondazione Matilde Tettamanti
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CARCIK CD123/33 in acute myeloid leukemia (AML) and Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Fondazione Matilde Tettamanti. Primary endpoint: Overall Survival at 12 months. Started Oct 2026; status: recruiting.
02
Drugs
CARCIK CD123/33
03
Conditions
acute myeloid leukemia (AML)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT07877610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877610.